Three month review delay in US sets Takeda's alogliptin further back in diabetes
This article was originally published in Scrip
Executive Summary
Takeda is facing an additional three-month delay with the US review of its type 2 diabetes drug alogliptin, and the fixed-dose combination of the product with pioglitazone, after the US FDA set a new Prescription Drug User Fee Act (PDUFA) action date of 25 April 2012.